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Abstract: The scientific community has made great efforts in advancing magnetic hyperthermia
for the last two decades after going through a sizeable research lapse from its establishment. All
the progress made in various topics ranging from nanoparticle synthesis to biocompatibilization
and in vivo testing have been seeking to push the forefront towards some new clinical trials. As
many, they did not go at the expected pace. Today, fruitful international cooperation and the wisdom
gain after a careful analysis of the lessons learned from seminal clinical trials allow us to have a
future with better guarantees for a more definitive takeoff of this genuine nanotherapy against cancer.
Deliberately giving prominence to a number of critical aspects, this opinion review offers a blend of
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state-of-the-art hints and glimpses into the future of the therapy, considering the expected evolution
of science and technology behind magnetic hyperthermia.
Keywords: magnetic hyperthermia; magnetic nanoparticles; hysteresis losses; cancer; magnetic
particle imaging; theranostics; nanoparticles synthesis; thermometry; standardization; nanotoxicity
1. Introduction
The scientific community involved with magnetic hyperthermia may be on the verge
of another turning point after some years without relevant news on the outcomes of
clinical research: new clinical studies on different indications are currently taking place.
For example, MagForce AG recently announced that its American subsidiary MagForce
USA, Inc. obtained approval from the U. S. Food and Drug Administration (FDA) for a
pivotal single-arm study for the focal ablation of intermediate-risk prostate cancer with
their NanoTherm® therapy system [1]. In Europe, both the Vall d’Hebron University
Hospital and the Fuenlabrada University Hospital are home to a new feasibility study on
treating locally advanced pancreatic ductal adenocarcinoma (PDAC) within the remit of
the NoCanTher project [2].
Without any doubt, behind the progress so far on the clinical translation of magnetic
hyperthermia, there is an ever more intertwined scientific network worldwide that is
keeping a constant influx of basic research, consolidating the developments under the light
of consensual new procedures, and expanding links with key actors in the translational
and clinical arena. International networking initiatives, such as the “RADIOMAG” COST
action [3], have helped in fighting against the geographical dispersion of scientific and
human resources related to magnetic hyperthermia, as well as eliminating duplication of
research lines and contributing to the harmonization of key concepts and procedures. In
any case, the cooperation between clinical and non-clinical worlds has become much more
fluid, as it should be to achieve a sustainable improvement in the coming decades [4]. The
existence of unique infrastructures for reliable, dedicated and widespread characteriza-
tion techniques for nanomedicines is paving the way for a faster translation of promising
nanoproducts. A supranational example is the European Nanomedicine Characterisation
Laboratory [5], created back in 2015 under the auspices of the H2020 framework program,
and a more established national example is the Nanotechnology Characterization Labo-
ratory in the USA, founded by the National Cancer Institute (NCI) in collaboration with
the FDA and the National Institute of Standards and Technology (NIST) [6]. However, as
it could not be otherwise, there are some important issues standing in the way of wider
clinical adoption of magnetic hyperthermia, some of which are common to many other
nanomedicines [7]. The economic burden of taking the leap from basic nanomedicine
research to translation [8] appears to be insurmountable in the opinion of the scientific
community, above all with the current funding schemes, which despite being regarded as
insufficient and poorly coordinated, are also beginning to suffer significant cuts. This is
exemplified by the recent turmoil around the decision of the United States National Cancer
Institute (NCI) in halting funding for the Centers of Cancer Nanotechnology Excellence
(CCNEs) [9], the commentary published by Kinam Park—the former Editor-in-Chief of the
Journal of Controlled Release—in favor of the controversial decision [10], and the counter-
reaction that followed from the board of the Nanomedicine and Nanoscale Delivery Focus
Group of the Controlled Release Society [11] and the former president of the European
Research Council [12].
Magnetic hyperthermia therapy mainly comprises two key elements: injectable mag-
netic nanoparticles (MNPs) and a magnetic field applicator, both of which were approved
in most cases as medical devices. At least in Europe, there is still a debate around whether
a more specific regulatory framework—beyond the more recent regulation (EU) 2017/745
on medical devices repealing the 93/42/EEC and 90/385/EEC directives—is needed for
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nanomedical devices. The matter only worsens when considering the process in different
pharmaceutical jurisdictions [13]. This uncertainty around well-defined pre-normative
and regulatory frameworks is discouraging private investors and pharmaceutical compa-
nies from taking the initiative in leading new industrial projects or sponsoring the most
promising current developments. Added to this is the reluctance to use MNPs in humans
after several cases of withdrawals of nanoproducts both from the market and from the
regulatory process, in addition to the abandonment of the production of other formulations
based on MNPs (see Section 5).
All these aspects, along with many others shaping the present and the future of
magnetic hyperthermia, are commented on here by international experts, taking the current
state-of-the-art as a starting point.
2. Establishing Standard Operational Procedures for Structural and Magnetic
Characterization of Magnetic Nanoparticles
Nowadays, nanomaterials manufacturers face a constant increase of requirements
regarding speed process and product quality control that need real-time characterization
techniques adapted to nanoscale metrology and standardized operational procedures (SOP).
Indeed, SOP and automated instrumentation for characterizing magnetic nanomaterials
will definitively benefit both the industrial demands in quality control and also basic
research. Recent initiatives, as the “RADIOMAG” COST action [3], showed significant
variability of results when comparing physical parameters, such as the specific absorption
rate (SAR) or specific loss power (SLP), obtained in magnetic colloids by different research
labs [14]. Moreover, many physical parameters of MNPs can be determined by distinct
characterization techniques (see Table 1), increasing the variability of the results. Hence,
there is a need for standardizing methodologies for characterizing extremely relevant
parameters such as magnetic losses of MNPs.
Table 1. MNP parameters and the corresponding characterization techniques. Adapted from [15,16]. See list of acronyms at
the end of the document.
Structural Properties
Particle, core and aggregate size TEM, XRD, DLS, NTA, SAXS, HRTEM, SEM, AFM, EXAFS, FMR, DCS, MALDI,NMR, TRPS, EPLS, magnetic susceptibility
Morphology TEM, HRTEM, AFM, EPLS, FMR, 3D-tomography
Elemental-chemical composition XRD, XPS, ICP-MS, ICP-OES, SEM-EDX, NMR, MFM, LEIS
Crystallinity XRD, EXAFS, HRTEM, electron diffraction, STEM
Structural defects HRTEM, EBSD
Chemical state–oxidation state XAS, EELS, XPS, Mössbauer
Ligand-binding, surface composition XPS, FTIR, NMR, SIMS, FMR, TGA, SANS
Colloidal Properties
Hydrodynamic and aggregate size NTA, DLS, DCS, UV-vis, SEM, TEM, Cryo-TEM
3D visualization 3D-tomography, AFM, SEM
MNP charge Zeta potential, EPM
Element concentration ICP-MS, UV-vis, RMM-MEMS, PTA, DCS, TRPS
Magnetic Properties
Quasi-static magnetization properties SQUID, VSM, Mössbauer, MFM, FMR, XMCD,
Dynamical magnetization properties AC susceptometry and magnetometry, magnetorelaxometry, magnetic particlespectroscopy
Magnetic losses AC calorimetry, AC susceptometry and magnetometry
Since this section focuses only on essential characterization techniques for magnetic
hyperthermia (MH) applications, it is worth noting that magnetic losses are strongly influ-
enced by MNPs parameters such as size [17] and shape [18,19], aggregation degree [20,21]
magnetic anisotropy [22], magnetic dipolar interactions [23,24], functionalization [25,26],
viscosity of the dispersion medium [27,28], and alternating magnetic field conditions
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(field frequency and amplitude) [29–31]. Several EU projects focused on standardization
and harmonization of analysis methods for MNPs have been/are being carried out, e.g.,
NanoMag, MagNaStand and RADIOMAG, as well as approved ISO standards (ISO/TS
19807-1:2019) [32,33]. These achievements benefit the preparation of SOPs for characterizing
relevant parameters such as magnetic losses of MNPs or the design of standard reference
nanomaterials to harmonize the comparison of results obtained by distinct research groups.
Hence, SOPs aim to homogenize procedures for characterizing physicochemical parameters
of magnetic suspensions as the first step towards International Standards. So far, efforts
with good results have been done to characterize and harmonize analysis methods for
both suspended and immobilized MNPs [15,16,33,34]. Here we spotlight selected essential
methods for MH application. A general description of analysis methods for magnetic
nanoparticle systems can be found in ref. [16].
2.1. Structural Characterization
Today, nanoscience cannot exist without near-field and electron microscopy techniques
such as TEM, HRTEM, SEM, EDX, AFM, etc. Within the latter, TEM is the most widely
used for the structural characterization of nanoparticles, which mainly comprises MNP
core size, core size distribution, shape, aggregation, etc. However, due to the inherent
sample preparation techniques, it is often difficult to preserve the original colloidal state.
In this sense, the use of cryo-TEM is encouraged to better capture the spatial arrangement
of MNPs, thus providing more accurate information about their aggregation state.
2.2. Colloidal Properties
These are generally characterized under random conditions, namely pure water,
buffers (often phosphate solutions), etc. A priori well-qualified samples, however, often
end up failing in vivo due to a significant loss of efficacy and/or the onset of toxicity [35].
The reasons behind this observation can be diverse: sample contamination, MNPs ag-
gregation, and interfacial interactions with cell membranes or blood components, among
others [36]. MNPs qualification must be performed under conditions that mimic the in vivo
environment, mainly pH and salinity, but also including proteins, carbohydrates and lipids.
In general, MNPs’ interactions at bio-nano interfaces are mainly determined by size, charge
and hydrophilicity/hydrophobicity [37]. In fact, these properties are closely related to
the parent colloid stability—via electric, steric and electrosteric stabilization—and particle
aggregation in poorly stabilized magnetic fluids. Dynamic light scattering (DLS) is one
of the most employed methods to measure hydrodynamic sizes and size distributions
in dilute colloids by analyzing the intensity fluctuation of scattered light caused by the
Brownian motion of the constituent nanoparticles. The main source of uncertainty here
is polydispersity, but in the literature, the “DLS size” is often provided without reporting
some relevant measurement conditions like pH or ionic strength, making it difficult to
establish the source of polydispersity. The latter could reside in the primary particles and
their aggregation due to weak colloidal stability [35], and it has a major impact both on
the sample’s shelf life and its subsequent use. For example, appropriate and inappropriate
MNP manufacturing has been illustrated in the literature by human blood smear tests [36].
MNP charge can be characterized via zeta potential (ζ) measurements, which is
not characteristic of surface charge as found in the literature [15]. It highly depends on
the pH and ionic strength of the medium and the quality and quantity of specific ions
(phosphates in buffers, carboxylates, surfactant ions, etc.). If MNPs are stabilized only
electrostatically, ζ values higher than |25–30| mV, measured at low ionic strength, indicate
good colloidal stability. At high salt concentration, ζ becomes zero. A null value also
occurs both at a pH coinciding with the isoelectric point and in the presence of specific
ions, causing ζ reversal. Consequently, reporting ζ values without providing information
on pH, ionic strength, specific ions, etc., of the dispersion solutions is meaningless. In the
case of concentrated magnetic suspensions and gels, DLS cannot be used; in these cases,
more powerful scattering methods such as SAXS and SANS are needed [38]. The core-shell
Materials 2021, 14, 706 5 of 36
structure and the probability of aggregation in samples can be measured in pristine samples
as used in bio-relevant media, even highly concentrated or embedded in a gel. The third
relevant colloidal parameter is the hydrophilicity/hydrophobicity of the MNP coating. Of
particular note in the case of MNPs intended for biological media is the protein adsorption,
leading to the so-called “protein corona” around nanoparticles since it masks the original
character of the MNP surface [35].
2.3. AC Susceptometry
In AC susceptibility (ACS) vs. frequency measurements, a sinusoidal magnetic field
of constant amplitude is applied over the sample, and the excitation frequency is swept at
a constant temperature [39–42]. A superimposed DC magnetic field can also be applied.
The AC field intensity is generally sufficiently small, fulfilling the low-field limit where the
magnetization is linear to the field. The in-phase component (real part) and out-of-phase
component (imaginary part) of the ACS are measured versus excitation frequency. In
order to calibrate the signal amplitude and phase, the system should be calibrated, e.g.,
with a sample with a known dynamic magnetic frequency response, for instance, the
paramagnetic material Dy2O3 in powder form [43]. This also allows to compensate for any
amplitude and phase errors and also to convert the measured ACS into a calibrated volume,
molar or mass susceptibility. ACS vs. frequency measurements have been routinely used
by numerous groups to characterize MNPs [43–46]. From the ACS response, it is possible to
estimate the SLP value by studying the magnetic losses obtained from the ACS out-of-phase
component [41,47].
In AC susceptibility vs. temperature measurements at constant excitation frequency, a
small amplitude sinusoidal magnetic field is also used, and its frequency can be varied up
to about 10 kHz [48]. In a recent paper, an induction-based ACS system that can be used at
lower temperatures was designed for frequencies up to the MHz range [49]. Calibration
is done in almost the same way as the ACS vs. frequency method using a sample with
known dynamic magnetic properties. The in-phase and out-of-phase components of the
ACS are measured versus the temperature of the sample. In addition, in this case, a
superimposed DC magnetic field can be applied. In a specific temperature range, the
response becomes frequency-dependent, and the ACS results provide information about
the magnetic relaxation properties of the MNP ensemble [49–55]. Thus, measuring the
dynamic magnetic properties gives information on the magnetization dynamics in the
sample by varying the AC drive frequency (different time scales). Temperature-dependent
ACS is a standard technique for characterization of MNPs, for instance, to determine
blocking temperatures, magnetic relaxation properties or magnetic interactions; indeed,
it is important to quantify magnetic interactions as they will affect the energy absorption
and, therefore, the hyperthermia heating properties [17,56–58].
2.4. DC Magnetization
In DC magnetometry (DCM), the magnetic moment of a sample is measured as
a function of both applied magnetic field and temperature. DCM measurements are
typically performed in commercially available magnetometers, based on SQUID techniques,
vibrating sample magnetometers (VSM) or alternating gradient magnetometers (AGM) [59].
The maximum magnetic fields in the DCM method should be large enough to saturate
the sample magnetization in order to determine the intrinsic saturation magnetization.
DCM magnetometers are calibrated against a magnetic sample with known saturation
magnetization or susceptibility. The basic parameters from a magnetization versus field are
intrinsic saturation magnetization, where the measured magnetic moment is normalized
to the mass or volume of the magnetic material under investigation. In addition, the
remanence and coercivity from the hysteresis loop can be determined. Likewise, the
absorbed energy by the MNP system at equilibrium can be obtained by calculating the
area enclosed under the hysteresis loop [60]. DC magnetization measurements constitute
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a basic magnetic characterization technique that has been routinely used by numerous
groups to characterize MNPs systems [61–64].
2.5. AC Calorimetry
Calorimetry is the most employed technique to quantify magnetic losses in MNP
suspensions subjected to an AC field. The procedure is based on measuring the initial
temperature increase rate immediately after applying the AC field. This experimental
method has been widely employed and has contributed to understand the influence of
intrinsic—structural, colloidal, magnetic—or extrinsic parameters—AC field—on SLP and
ILP values [20,23,24,26,30,31,36,47,56–58,63,65–68]. Calorimetric measurements are usually
performed under non-adiabatic conditions since adiabatic ones are rarely attained [69,70].
Such non-adiabatic systems require particular data analysis to remove artifacts from differ-
ent error sources [71,72].
2.6. AC Magnetometry
AC magnetometry quantifies the enclosed area of AC magnetic hysteresis loops to
determine SLP values (≈area under loops × field frequency). The application of this
technique to measure magnetic colloids is recent, and most of the obtained results have
been performed using home-made equipment [73–76] since commercial equivalents are
very scarce. AC magnetometry has the advantage that the calculation of SLP values is
not influenced by thermal parameters or conditions, allowing to quantify of magnetic
losses when MNPs are inside biological matrices, like cells or tissues [28]. The analysis
of hysteresis loops under AC fields can shed light on the effect of particle size, shape,
aggregation, anisotropy, viscosity and field amplitude and frequency on the magnetic
losses [27,28,77–79]. However, dedicated SOP are also needed for this technique.
In summary, the existence of SOP and automated instrumentation to quantify relevant
physicochemical parameters to magnetic hyperthermia will warrant the reliability and
reproducibility of the obtained values, which is mandatory to ensure a reliable translation
of MH to clinics.
3. Scalable Synthesis Protocols
3.1. General Challenges
Today’s literature provides a variety of protocols to synthesize uniform ferrite MNPs
with different sizes and shapes, suitable for magnetic hyperthermia [80]. In many cases,
reported nanoparticle properties are superior to those of currently approved products
and, therefore, have the potential to increase the efficiency of hyperthermia treatments by
reaching higher temperatures at lower nanoparticle concentrations under milder magnetic
field conditions. However, large-scale production of these MNPs with improved or optimal
properties is associated with obstacles such as low yield and, most importantly, limited
reproducibility due to poor control and documentation of synthesis conditions. These
challenges need to be addressed for a synthetic product to reach market maturity.
On the other hand, a current research challenge is understanding nanoparticle forma-
tion mechanisms and kinetics that are essential to guide the development of syntheses that
are reproducible in a systematic, controllable and scalable manner. Since continuous pro-
cesses can provide advantages over batch processes for reproducible and scalable synthesis
protocols, they have recently gained increased interest.
The final step related to nanoparticle functionalization is still a difficult task that needs
special attention to achieve scalable production. The coating and the number of active
surface sites are crucial for nanoparticle dispersion/stability, and therefore particle–particle
magnetic interactions and the particle heating properties independently on the media
viscosity and the concentration, i.e., in vitro and in vivo conditions. It is important to
establish a reproducible yield of the coating step and purification of any byproduct.
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3.2. Preparation of MNPs and Functionalization
We have identified some major challenges in the preparation of uniform MNPs with
different synthetic methods, classified by the media where nucleation and growth take
place, i.e., aqueous and polar or nonpolar organic solvents. We focus on magnetic iron
oxide nanoparticles (IONPs) as they have already been approved for humans [81] and are
therefore the most promising heating agent candidates.
The main challenge of synthesizing IONPs for hyperthermia in aqueous media is the
production of large (~20 nm) particles with good control of size and shape distribution.
Despite progress and broad utilization of the water-based co-precipitation method due
to the high yield, there are several drawbacks, such as suboptimal size (<15 nm, with
exceptions, e.g., for methods with a slow pH increase [82]), high polydispersity, poor
crystallinity control, and consequently poor saturation magnetization. Regarding larger
particles for hyperthermia application with saturation magnetization values near the bulk,
they can be obtained by oxidative precipitation of Fe(II) salts in aqueous media (>15 nm).
Recently, oxidative precipitation has been scaled up to 20 g per batch [83] and was made a
continuous process [84,85]. The combination of low-cost reagents such as FeSO4, NaOH,
NaNO3 and ethanol/water mixtures was shown to yield uniform nanoparticles.
The main challenge for thermal decomposition synthesis in high boiling point organic
media (commonly nonpolar solvents such as 1-octdecene or polar polyol solvents) is the
standardization of experimental procedures and control of synthetic conditions. This is
due to the complexity of the formation process of magnetite and the consequence of a set
of thermally activated chemical reactions [83]. Even subtle changes of chemical aspects
such as precursor/reagent concentration can provoke considerable modifications of the
decomposition and or nucleation temperature with dramatic consequences on the final
nanomaterial product.
One parameter deserving special attention is the heating rate, as it is known to af-
fect (or used to control) nanoparticle sizes [86]. Since the heating rate can vary with the
experimental procedure, for example, the size and geometry of the reaction vessel (with
limits for larger volumes in terms of heat input), reproducing heating profiles from small
to especially large-scales is not trivial. Temperature profiles of the reaction media should
therefore be documented carefully; reporting heater settings is not enough. Considering
scalable production, efficient heating sources are required to facilitate homogeneous tem-
perature profiles (here, the mixing system plays an important role) and sufficient heating
rates. Heating via microwave radiation is a promising alternative to classical heaters and
was shown to enable scale up the production up to 1 kg [87]. Microwave heating was also
used to synthesis of flower-like multi-core IONPs with good control over core sizes and
fusion between them depending on the reagents, temperature and heating time. Other
heating systems such as hydrothermal using autoclaves presents the drawback of needing
a special pilot plant to scale up safely the lab-scale procedure.
In addition to heating rates, also reagent storage, purity and supplier, stirring con-
ditions (stirring speed, type and dimension of propeller/stirrer used), inert/non-inert
gas conditions during synthesis [88] and washing/centrifugation protocols need to be
documented and/or recorded accurately during synthesis to obtain good reproducibility.
Only accurate documentation, and reporting, allows researchers in other laboratories to
run a thermal decomposition synthesis “in the same way”, i.e., at best possible degree of
similarity.
Although (classical) thermal decomposition syntheses in nonpolar solvents can yield
magnetic particles with excellent size and shape uniformity, as well as crystallinity and
magnetization, they are very high in price, especially due to expensive organic precursors,
and generate many byproducts. Polyol methods are usually cheaper, but scalable protocols
to synthesize particles for magnetic hyperthermia are still at the research stage.
Functionalization is another significant aspect, which draws interest when aiming to
use nanomaterials for magnetic hyperthermia. Much work has been done in this aspect, and
the protocols for coating the nanoparticles with layers of organic or inorganic agents and
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their functionalization depending on the application are generally well-established [89].
Their limitations are well-known and often related to the large polydispersity that is
generated by the coating of aggregates, the limited colloidal stability and its degradation
when stored for a long time. Most protocols use highly diluted suspensions and are difficult
to scale up. A special problem that needs more attention is related to the overall influence
of the coatings on the hyperthermia performance in vitro and in vivo.
3.3. Improving Reproducibility
In order to improve the reproducibility of all MNP synthesis, we need to develop
detailed reports of methods and procedures, including used chemical reagents (e.g., purity,
supplier, and product code), as well as SOPs that should be published as supplementary
info with the paper to be able to become bench-mark syntheses for the community. In the
same way, accurate reporting of characterization protocols is essential. The use of ISO stan-
dards that are internationally agreed by experts and guaranteed quality requirements (e.g.,
analysis of TEM images, usage of Scherrer equation, DLS for size, ζ-potential, VSM-SQUID
for magnetic properties, TGA for the determination of the amount of organic material at the
particles surface, ICP-OES elemental analysis for pure metal content quantification) should
be used [15]. A good practice is the publication of raw data (especially TEM images, where
an image is not presentative due to a limited number of particles that can be observed).
In fact, in many cases, there is a need to use a combination of different characterization
techniques in order to get a full detailed and reliable picture of a given sample. Already
published ISO standards can help in the comparison of the results and the samples.
In the same sense, the development of broadly accepted protocols for the magnetic
characterization of hyperthermia-targeted nanoparticles will help to provide a higher
degree of reliability of hyperthermia measurements at an internationally accepted level. In
this way, the measurement of both SLP and ILP (to compare measurements performed at
different frequencies and field strengths or using different instruments) will be more easily
comparable among all academic and non-academic partners. These characterizations will
concern all possible forms, such as colloidal dispersions/ensembles and powder samples.
Detailed characterization of the nanoparticles is of outstanding importance for establishing
a reproducible synthesis.
3.4. Scalability Possibilities
Production at larger scales can easily be achieved due to repetitive and parallel
production, but syntheses using lab-scale reactors (<100 mL) will hardly be cost-effective.
Only in few cases, the solubility of reagents allows the large production by increasing the
reagent concentration while keeping the same solvent volume [83]. In most cases, keeping
the precursors/surfactants/solvents ratio while scaling-up a given reaction is not enough
to assure its reproducibility in those larger scales unless demonstrated. It should be taken
into account that the gap between the ordinary laboratory scale (100 mL) and the industrial
pilot plant scale (100 L) is three orders of magnitude. Experiments of scaling up to 10 L
that still could be done in the lab are needed before going to the industrial scale.
The key for a successful scale-up is to understand the synthesis’ critical process param-
eters, i.e., parameters with a high impact on the nanoparticles’ critical quality attributes (for
example, in the case of hyperthermia, particle size distribution, surface functionalization,
and most importantly, the SLP). Hence, understanding nanoparticle formation mechanisms
and kinetics are important as it shows, for example, if mixing times, heating rates, or
reagent addition time scales (or a combination) is crucial, i.e., it needs to be maintained at
larger scales.
An interesting option to produce MNPs at larger scales is the continuous syntheses at
low [85,90–92] and high temperatures [93–96] (Figure 1). Both processes can be automatized
at a laboratory scale, but up to now, none of them have been passed to an industrial pilot
plant scale.
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further, that each patient ill need six cycles of treatment a year requiring each time 0.3 g of
MNPs [97], the global demand would be 144 tons a year. We need to improve the heating
efficiency of IONPs, let us say three times more, to reduce the amount of MNPs needed for
each time to 0.1 g. Although this production rate appears challenging, it must be considered
together with the production costs. Assuming that costs of $100 per treatment with the
nanoparticles are acceptable, a reasonable cap for production costs might be $50/g (5% of
treatment costs). Although this is an extremely oversimplified estimation, it indicates what
can be considered as an economic large-scale synthesis of MNPs for hyperthermia, i.e., a
process capable of reproducibly producing the desired nanomaterial at costs < $50/g. In
biomedical applications, when a small amount of nanoparticles is needed, an alternative to
scaling the production of MNPs could be the translation of the synthetic process towards a
dose-on-demand synthesis in the clinic [98,99].
4. Long-Term Stability and Biodistribution of Nano-Heaters in Humans
One key issue in the use of magnetic nanoparticles for magnetic hyperthermia therapy
is their biodistribution, biotransformation and long-term fate in the body.
A first concern is to define the time window of magnetic hyperthermia efficacy, i.e.,
how long the particles will keep their magnetic properties and will be able to heat. The
subsequent clinical challenge is to define the number and the time of magnetic field
applications that will be useful to affect the tumor.
It has been shown that intracellular confinement of magnetic nanoparticles in lyso-
somes has a dramatic impact on their dynamical magnetic properties and SLP, mostly due
to dipolar interparticle interactions and loss of rotational mobility [100,101], even if the
particles keep their crystalline integrity. Another critical aspect is that the intracellular
magnetic particles are exposed to the harsh environment of lysosomes that combine acidic
pH (about 4.5), enzymes that regulate protein degradation and redox regulators. Since the
function of lysosomes is to degrade undesirable proteins and xenobiotics, it is important to
determine to what extend lysosomes may be able to degrade magnetic particles and make
them lose their structural integrity and magnetic properties?
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In vivo studies in mice revealed that intravenously injected IONPs lose their magnetic
properties once accumulated in the liver and spleen over months after injection [102,103].
In this regard, it was critical to develop nanometrology methods to quantify the magnetic
properties of nanoparticles in organs over time after their administration. Elemental analy-
ses such inductively coupled plasma mass spectrometry(ICP-MS) or inductively coupled
plasma atomic emission spectroscopy (ICP-AES) as ICP-MS or ICP-AES measure the total
iron concentration in a sample but cannot distinguish between endogenous iron—naturally
present in the body—and exogenous iron coming from injected nanoparticles and between
magnetic and non-magnetic iron. In contrast, magnetization measurements or ferromag-
netic resonance (FMR) (also called electron paramagnetic resonance (EPR)) can be adapted
to tissue samples to specifically quantify the magnetic properties in organs or cells and
identify the evolution of the magnetic behavior of nanoparticles in different tissues [102]
(Figure 2). Although these metrology methods provide quantitative information on the
global magnetic properties of a tissue sample (loss of magnetization or modification of
magnetic dynamics can be due both to degradation of nanoparticles and/or leak/transfer
to other tissues), direct observations at the nanoscale are also required to assess in situ the
structural biotransformation of nanoparticles in their microenvironment. Remarkably, the
first non-ambiguous proof that IONPs are locally disintegrated within lysosomes in vivo
was provided using iron-oxide-coated-gold nanoparticles [103]: iron oxide crystalline shell
was shown to disappear around the gold core within lysosomes of spleen and liver cells.
Interestingly the degradation kinetics depend on the initial coating of nanoparticles, shape,
size and dose injected [103–105]. Iron oxide nanocubes, for example, are first eroded start-
ing from the corners of the cube, where the polymer layer is the less dense [106] (Figure 2).
Eroded nanoparticles preserve their crystalline structure. In vivo experiments also shed
light on the recycling process of iron originating from the degradation of nanoparticles.
This answers the second concern of nanoparticle administration in the body: what is the
long-term fate of the magnetic particles? What about the product of degradation? TEM
observations from in vivo tests with mice revealed the increased presence of iron-filled
ferritin protein inside and outside the lysosomes, close to intact or degraded nanoparti-
cles [102,107]. This raised the hypothesis that ferritin, the protein in charge of iron storage
and regulation, could accumulate iron coming from the degradation of nanoparticles,
which is consistent with the overexpression of ferritin-related genes a few months after
nanoparticle injection. In vitro studies have indeed demonstrated that apoferritin has not
only the ability to accumulate iron coming from the degradation of nanoparticles in an
acidic lysosomal like environment but that it can also regulate the nanoparticle degradation
and iron recycling, which is consistent with the role if redox regulator of ferritin inside the
cells [108]. Moreover, cobalt was also detected in ferritin proteins localized in lysosomes
of liver tissue in mice injected with cobalt ferrite nanoparticles [109]. This highlights that
endogenous ferritin proteins can locally accumulate metal ions originating from the lyso-
somal degradation of nanoparticles, including at least iron and cobalt. Ferritin recycling
and regulation of nanoparticle degradation in lysosomes can be a strategy to limit the
toxicity of free iron ions mediated by the Fenton reaction. Hence, the finely regulated iron
metabolism in the organism is a crucial asset for the clinical use of IONPs, which benefit
from physiological iron ferritin storage to avoid toxicity at least at low doses.
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ex vivo electron paramagnetic resonance (EPR) quantification in organs, TEM observations of intracellular distribution and
morphological biotransformations (reproduced with permission from [104].
Although in vivo studies have been instructive to reveal the long term fate of magnetic
particles, methods to monitor quantitatively their structural integrity remained challenging
to implement in situ, within the cells, and in the long-term [110]. One emerging approach
is to use cell spheroids [111,112], which stands as a closed system allowing them to be
kept in culture for long (up to a few months for stem cells-based spheroids, Figure 3A),
and harboring nanoparticles within each of the component cells, internalized right before
spheroid formation. Multiscale physical measurements (magnetism, calorimetry, optics)
can be performed quantitatively at the single spheroid level and qualitatively by imag-
ing at the nanoscale. First, the spheroid magnetism is a direct fingerprint of nanoscale
transformations. Figure 3B shows typical spheroid magnetization curves at different time
periods, up t one month, evidencing a massive degradation of the nan particles inside the
spheroid over time [111]. This is confirmed by electron micros opy observation (Figure 3C),
as well as the appearance of multiple ferritin nanopa ticles while lmost no nanoparticles
remain intact for lo g time peri ds [111,112]. Unfortunately, this degradation transl tes
into a loss of hea generation at he spher id level u on magnetic hyperthermia applica-
ion [112], ra sing an issue for sequential magnetic hyperthermia ap lication n therapy.
However, strategies have emerged to prevent the biodegrada ion of the magnetic cor
and, in turn, preserve magnetic hyperthermia functionality. O e of them is to shield the
magnetic core with an in rt gold sh ll [112,113], and another one is to protec the core
with a polymer coating [114]. Alternatively, another strategy could be to seize the capacity
that some human cells must biosynthesize magnetic nanoparticles anew from the iron
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delivered by the degradation of synthetic nanoparticles, thus providing the cells with
biogenic non-degradable nanoparticles and long term magnetism [115,116].
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Figure 3. Intracellular biodegradation of MNPs monitored within cell spheroids as tissue model.
(A) The spheroids are formed from 200,000 stem cells, which spontaneously regroup into a cohesive
spherical aggregate that can be kept in culture over a month without experiencing any cell mortality
or tissue necrosis. (B) Magnetometry can be performed at the single spheroid level, evidencing a
massive degradation of the nanoparticles in a few days after internalization. (C) TEM images one
month aft r na opart cle int rnalization, demonstrating that only a few intact anoparticles remain
within the endosomes (white arrow) while both endosomes and cytoplasm are fill d with the ferritin
protein (black arrows) containing the iron released from degradation, with a diameter 5–7 nm as seen
in the close-up image on the right. Reproduced with permission from [111].
5. e lat r tes t li ical r al a ercial tat s
ey to the clinical development of magnetic nanoparticle hyperthermia is the availabil-
ity of clinically approved, commercially available MNPs. While a profusion of research over
the past 20 years has focused on optimizing novel nanoparticles for hyperthermia [117], to
date, only a handful of formulations have been approved, and only one for hyperthermia
(Table 2).
It should be noted that there is no intrinsic regulatory barrier to the approval of
magnetic nanoparticles for clinical use. Indeed, the first iron-oxide formulations were
approved in the mid-1990s in Europe, the US and Japan as MRI contrast agents [118].
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These particles showed themselves to be generally safe and effective, although most have
since been withdrawn as the imaging market moved away from iron oxide agents to favor
Gadolinium-based ones.
Table 2. Commercially available clinically approved IONPs.





Iron deficient anemia in








glioblastoma 2010 (CE mark) Device (class III)
Magtrace®c Endomag
Sentinel lymph node






a Approved by the EMA as Rienso® in 2012, but withdrawn in 2015 [119]; b approved by the EMA in 2001, but European distribution
ceased in 2009 [120]; c formerly known as Sienna+®.
However, even for MNPs that have been successfully manufactured in the lab and
shown promising performance in in vitro and small animal studies, the route from research
to regulatory approval and commercialization is complex, expensive and time-consuming,
with many aspects to consider at each stage (Figure 4). Undoubtedly this has proven a
barrier to the clinical translation of magnetic hyperthermia. Each step requires significant
investment, and failure at any stage can lead to delay or discontinuation of the product.
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stable over desired shelf life, and failing to account for the specific regulatory require-
ments for the territory where approval is being sought. One area of particular challenge 
is establishing a particle manufacturing process to GMP standards. Involving a contract 
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the manufacturing risk. 
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quality standards both for the research market and, for some, as a step towards clinical 
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These steps will not be explored in detail here, but common pitfalls include: using
preclinical models that do not translate accurately to the clinic; using lab-scale processes
that are not readily scalable to volume manufacture; not considering biocompatibility
early in the development; product in its final packaging not being physically or chemically
stable over desired shelf life, and failing to account for the specific regulatory requirements
for the territory where approval is being sought. One area of particular challenge is
establishing a particle manufacturing process to GMP standards. Involving a contract
manufacturing organization (CMO) with the specialist skillset required can help to reduce
the manufacturing risk.
5.1. Preclinical Stage
A number of companies have progressed towards addressing manufacturing and
quality standards both for the research market and, for some, as a step towards clinical
approval (Table 3). The primary focus has been on size distribution, magnetic performa ce,
or coating properties, and only a few make claims to GMP manufacturing, a prerequisite
for clinical translation.
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Table 3. Selection of commercially available research-grade MNPs.
Manufacturer Name(s) Development Stage
chemicell GmbH fluidMAG and nano-screenMAG Research
Creative Diagnostics Various product codes Research
Imagion Biosystems PrecisionMRX® Research
Liquids Research HyperMAG™ Research
Magnetic Insight VivoTrax™, VivoTrax Plus™ Preclinical sterile
micromod Partikeltechnologie GmbH nanomag®, Perimag®, Synomag® and others GMP manufacturing available
Nanopartz Various product codes GMP manufacturing available
nanoPET Pharma FeraSpin™ Preclinical sterile
nanoTherics HyperMAG® Research
NNCrystal Various product codes Research
NVIGEN MaxVigen™ Research
Ocean NanoTech Various product codes Research
Resonant Circuits RCL-01 Preclinical sterile
SPL Medical Ferrotran Undergoing human clinical trials
Currently available magnetic particles are predominantly iron oxide-based, which
is understandable given its history and safety profile. Optimization for hyperthermia
may necessitate looking beyond mixed-valence iron oxides [121], but any novel material
will need to pass through toxicity screening and full development to deliver a significant
advance in clinical use.
5.2. Clinical Stage
Each health authority has different sets of requirements for regulatory approval, but
the basic elements are similar: In order to achieve approval to sell a magnetic hyperthermia
particle product, the manufacturer needs to demonstrate that the product is safe to use,
works effectively as a treatment in its chosen clinical indication, and is manufactured under
an appropriate quality system to ensure consistent product quality.
The first question to determine is whether the product is a drug or a device. Each regu-
latory agency has its own definitions (Table 4), but in general, drugs achieve their intended
purpose through chemistry (primarily pharmacology, metabolism) while devices work
through physics. A particular challenge of the nanoscale is that the dividing line between
“physics” and “chemistry” can be less distinct. Drugs and devices have different regulatory
pathways with distinct clinical requirements [122] (Figure 5); hence this determination
critically influences the course of the development.
Devices are assigned a class (I, II, or III) depending on the level of product risk, which,
in turn, determines the scope of development. The pathway for a lower risk device is
likely shorter than a typical drug pathway. Hyperthermia nanoparticle device products are
classified as class III in Europe under the medical device regulations (MDR) as they contain
nanoscale materials [123]. The US FDA also has classified its first approved nanoparticle
device product in class III [124].
5.2.1. The Importance of Primary Mode of Action (PMOA)
The drug/device definitions make clear that the “primary mode of action” (PMOA) or
the way in which the “primary intended purpose” is achieved is critical to deciding whether
a product is a drug or a device. If the primary way in which the product achieves its in-
tended purpose is through chemical (primarily pharmacological) action or via metabolism,
then it is a drug; if it does not, it is a device. In theory, this means that the same compound
or substance could be a drug in one indication and a device in another, and this can be
seen in the case of IONPs. Feraheme® and Resovist® are approved as drugs because they
achieve their PMOA via metabolism or pharmacology; while Nanotherm® and Magtrace®
are classified as devices because they achieve their PMOA via non-pharmacological, non-
metabolic means, in this case, magnetic heating and magnetic sensing, respectively. For
magnetic hyperthermia, a device PMOA is appropriate if the main intended purpose is
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achieved through magnetic heating of the nanoparticles, a physical mode of action not
involving pharmacology or metabolism. This has proven to be the case for the Nanotherm®
particle, which has been approved as a device in Europe [125] and is progressing on a
device pathway in the United States.
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Table 4. EU and US regulatory authority definitions of drug and medical device (emphasis added).
Regulatory Authority Drug Medical Device
European Union [126]
Any substance or combination of
substances
• having properties for treating or
prev nting disease in human beings
or;
• may be used in or administered to
human beings with view to restore,
correct, modify physiological
function
by exerting a pharmacological,
im unological or me bolic action, or
to making a medical diagnosis.
Any instrument, apparatus, appliance, material,
software, or other article [ . . . ] to be used in humans
for the purpose of:
• diagnosis, prevention, monitoring, treatment or
alleviation of disease,
• diagnosis, monitoring, treatment, alleviation of
or compensation for an injury/handicap
• investigation, replacement, modification of the
anatomy; control of conception
and which does not achieve its principal intended
action in or on the human body by pharmacological,
immunological or metabolic means, but which may
be assisted in its function by such means.
FDA [127]
(A) articles recognized in the official
United States Pharmacopoeia [ . . . ]; and
(B) articles intended for use in the
diagnosis, cure, mitigation, treatment,
or prevention of disease in man or other
animals; and (C) articles (other than
food) intended to affect the structure or
any function of the body of man or other
animals; [ . . . ]
an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar
or related article, including any component, part, or
accessory, [ . . . ]
which does no achieve its primary intended
purposes through chemical action within or on the
body of man or other animals and which is not
dependent upon being metabolized for the
achievement of its primary intended purposes.
A secondary mode of action may be included without affecting the determination. For
example, a hyperthermia particle may be intended to be metabolized eventually, but only
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after it has achieved its PMOA of heating. Therefore, the primary mode of action would
remain as a device.
5.2.2. Drug-Device Combination Product
Where a product uses both drug and device functions to achieve its primary intended
purpose, it is classified as a drug-device combination product [128]. A hyperthermia
particle that has a targeting function using a receptor (i.e., chemical/pharmacological
action), as well as heating, would be classified as a combination product. For combination
products in the US, the primary mode of action determines whether the primary regulatory
pathway will be drug or device. In Europe, combination products are either regulated
as drugs or devices depending on the primary versus ancillary function. For particles
combining more than one type of action, the appropriate regulatory pathway will depend
on which mode of action is primary, and typical elements of both the drug and device
pathway are followed, depending on the territory.
5.3. Streamlined Development
Any would-be hyperthermia therapy will need to demonstrate clinical safety and
efficacy, and for this, there is no short-cut, but there are ways to streamline the overall
process. One approach is to use an existing particle in a new way. Such “re-purposing” is
the basis for physician-led “off-label” use of therapies. For example, there are a number of
clinical studies investigating the use of particles approved for iron-replacement therapy
as MRI contrast agents [129]. The rationale is that if a product is shown to be safe in one
clinical indication, it will be easier to establish safety in a new one.
The process can also be streamlined by taking into account the requirements of later
stages, even in the earliest stages of particle development. Ensuring that manufacturing
questions such as toxicity, biocompatibility, stability and process scalability are consid-
ered early on can direct the development away from “dead-ends” and save significant
cost and time. For example, another nanotechnology, quantum dots, show promise for
cancer therapy. However, at first, the most commonly used cores contained cytotoxic
cadmium [130]. While in theory, these cores could be coated to minimize cytotoxicity, in
practice, establishing long-term safety has proved challenging. Initial consideration of
biocompatibility could have accelerated progress towards clinical use by directing effort
towards the cadmium-free non-toxic alternatives now being explored [131].
In summary, the challenging later stages of magnetic particle development can be
more easily negotiated if, at the early-stages, downstream requirements such as GMP
manufacture, clinical safety and the regulatory pathway can be incorporated and used to
guide the development. This kind of integrated approach can help hasten a bright future
for clinical magnetic hyperthermia.
6. Nanotoxicity of Nanoparticles for Magnetic Hyperthermia
The increasing use of magnetic hyperthermia in (pre)clinical settings warrants a proper
understanding and careful evaluation of how engineered nanomaterials would be most
optimally suited. This concerns both the efficacy of thermal conversion, with maximal
heat generation for a minimal number of nanoparticles, as well as a complete lack of any
potential toxicity on healthy cells from the patient. To date, various studies have looked
into the toxicity of IONPs, mainly driven by their clinical acceptance as contrast agents
for MRI [132,133]. The majority of these studies concern in vitro experiments, where cell
types of interest are used to evaluate potential toxicity upon exposure to the engineered
nanoparticles [134,135]. While more limited, some studies have also been performed in
preclinical animal models, mainly mice and rats, to evaluate potential systemic toxicity
from exposure to the nanoparticles [136].
However, final conclusions regarding the safety or toxicity of these nanoparticles
remain difficult to answer, mainly driven by the wide variety of model systems used, ex-
perimental settings and nanoparticle properties [137]. Overall, it is believed that IONPs are
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fairly safe, up to concentrations of 5 mM of iron [138]. Yet, these early opinions have been re-
visited by various studies, showing that nanoparticle-specific properties such as size, shape
and surface chemistry can have a significant influence on the toxicity of the particles [139].
Overall, toxicity has mainly been linked with cellular uptake levels, where IONPs tend
to cause high levels of reactive oxygen species, which, depending on the nature of the
cells, can lead to oxidative stress [140]. This, in turn, can manifest itself in different ways,
potentially resulting in genotoxicity, diminished stem cell differentiation, neurotoxicity or
inflammation [141–144]. In view of cancer therapy, the sequestration of dextran-coated
IONPs by tumor-associated macrophages has been shown to alter macrophage status and
promote proinflammatory M1 phenotype [145]. While this is potentially interesting for
tumor immunotherapy, the effect of the particles on other macrophages and the induction
of inflammatory responses may cause severe side-effects.
As mentioned above, one main problem lies in the seemingly contradicting data
available in the literature, which can be narrowed down to experimental variations. Minor
modifications to nanoparticle properties can have major implications in view of their
biodistribution and toxicity, and, therefore, no general conclusion can ever be made. IONPs
also interfere with various classical biochemistry tests, such as the MTT assay [135], and
care must be taken to properly design studies with suitable controls or in interpreting
data from other studies. For IONPs, one aspect of interest is their biometabolism, where
cellular uptake of the nanoparticles results in their lysosomal sequestration. There, the low
lysosomal pH and presence of small molecules (e.g., citrate) result in the dissolution of the
nanoparticles and the release of ferric ions that are then shuttled into the cytoplasm and
become part of the cellular labile iron pool [138]. While this degradation results in proper
bioprocessing of the nanoparticles, it will affect the magnetic properties of the nanoparticles
in the longer term [146,147]. In the short-term, the kinetics of this degradation must be
carefully controlled, as rapid dissolution is linked to excessive ferric ion concentrations
present locally that can surpass toxic thresholds [148]. Carefully controlling the degradation
kinetics by tuning nanoparticle properties, such as the surface coating, can play a key role
in determining the tolerance of the body to such nanoparticles.
In order to further exploit the clinical use of these nanoparticles in hyperthermia
applications, it is imperative that the scientific question is properly posed. The question:
“are nanoparticles safe” is too generic and can simply not be answered. By rephrasing
the sentence into “does formulation x cause any harm when it is used for hyperthermia
when administered by y at dose z?”, it defines better the research that needs to be per-
formed in order to promote this field: (1) the exact nanoparticle formulation must be
well characterized and described. (2) The route of administration to the patient must
be clearly defined. (3) The dose and need for repeated administrations or not must be
specified. (4) The ability to perform hyperthermia at its optimal output must be evaluated
and compared to current gold standards and state-of-the-art methods. While large sets of
literature data are available, the data needed to answer the question above remain scarce.
Typical examples include classical toxicity studies, in which nanoparticles are administered
systemically by intravenous administration, while for most hyperthermia applications, the
nanoparticles are administered locally. IONPs have been studied, but other nanomaterials
that are evaluated as hyperthermia mediators with possibly higher therapeutic efficacy are
often less commonly studied [149,150]. The biodistribution of the nanoparticles released
from the tumor after hyperthermia application would be more interesting to study than
systemically administered nanoparticles. The toxicity of the nanoparticles on their own is
important, but their effect must also be evaluated after hyperthermia application. It is likely
that the surface coating of the nanoparticles has changed due to the generated heat, and
this may affect nanoparticle behavior (biodistribution and toxicity) quite drastically. Apart
from safety, the therapeutic efficacy must also be demonstrated. While this commonly
happens using classical treatment (e.g., doxorubicin), this is often far from reality, and
clinically relevant treatments, as well as other novel state-of-the-art therapies, must be used
as a comparison (e.g., small molecules, immunotherapy, etc.).
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The clinical acceptance of a particular nanoparticle formulation also requires regu-
latory approval. While guidelines for chemicals to pass clinical trials are rather clear, for
nanoparticles, this remains rather vague. Progress has been made, however, and with
further optimization and teamwork between experts in the field, the throughput of clinical
translation of nanomedicines will only increase. Thus, further advances in the clinical trans-
lation of nanotechnologies can be expected in the near future [151]. To date, nanoparticles
can either be labeled as a “medical device” or as a “drug”, which has major implications on
how regulatory approval for clinical use can be obtained. The label of “medical device” was
previously preferred as it involved less lengthy clinical studies and was based on the notion
that the nanoparticles themselves did not change or were an active substance but merely a
tool by which therapy could be performed. As described in the excellent manuscript by
Jones et al. [152], the slow progress in clinical translation is not in itself caused by a lack of
regulations but rather a broad gap between theoretical knowledge and practice. This is in
part due to the lack of academics involved in setting up the documents regarding safety
and efficacy testing of medical devices, resulting in a lack of standardized methods for
gathering and presenting data. Efforts to bridge this gap are ongoing, with the setup of the
Nanotechnology Characterization Laboratory (NCL) to develop standardized protocols
for toxicology, pharmacology and efficacy evaluation of nanomaterials. For most agents,
the use of specialized clinical research organizations (CROs) is warranted, who will design
and/or perform the preclinical studies required to file an application for clinical studies.
While various CROs exist with broad expertise in a wide range of technologies, CROs with
expert knowledge on nanoparticle use remains limited. Progress in this domain is expected
as the field of nanomedicine keeps expanding, where nanotoxicity and nanomedicine
experts can then liaise with, or form part of, regulatory offices and CROs dedicated to
enhancing clinical progress in this exciting field.
7. Temperature Measuring and Monitoring
7.1. Background
Apart from their general application for distance controlled non-contact heating,
MNPs provide an excellent opportunity for nano-actuation. For instance, they can be
used for selective heating of nano-objects to induce point reactions at the nanoscale. This
operation implies the generation of temperature gradients in the nano-object with respect
to its surroundings, which can only be determined by thermometers with a spatial reso-
lution also at the nanometre scale. Moreover, the simultaneous use of nanoheaters and
nanothermometers could be employed to investigate phenomena of heat transfer at the
nanoscale, which is actually an unexplored territory and the object of intense debate,
especially concerning intracellular heat transfer [153,154]. The recent development of
rare-earth-doped luminescent MNPs has introduced a new field in thermal biosensing,
implying less invasive experiments, not only in living cells but also in more challenging
small animal models [155–158]. Joining thermometry and heating at the nanoscale can
also be particularly interesting for the development of high-performance non-invasive
hyperthermia therapy based on the local heating of specific intracellular sites to provoke
cell apoptosis, without the need of overall massive heating of the whole cancer tumor.
The hypothesis of local intracellular hyperthermia arises from the drawbacks of
the current strategy of overall tumor heating and a massive injection of MNPs directly
into the tumor [159]. Even before being tested, this hypothesis has already been the
subject of intense debate [160]. Objections come mostly from standard thermodynamic
considerations, which estimate an intracellular concentration of MNPs required to eradicate
tumors that is virtually unfeasible [160]. At the center of this debate is the question of
whether it is possible to create a sufficiently high-temperature gradient in the vicinity of
MNP dispersed in a liquid or intracellular media [154]. Indeed, theoretical thermodynamic
calculations predict the formation of negligible temperature gradients in MNPs when
subjected to alternating magnetic fields with respect to the bulk [161,162], and a few
experimental reports are in agreement with these predictions [163]. However, numerous
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experimental studies have found substantial local temperature gradients at these conditions
that suggest the existence of nanoscale heat transfer phenomena different from macroscopic
system behavior [160,164–169]. It is thus peremptory for the advancement in the field to
dispose of reliable methods for the determination of local temperature in the vicinity of
MNPs, and the derivation of thermodynamical models for intracellular heat transfer at
the nanoscale.
7.2. Luminescence Nanothermometry
Luminescence thermometers are probably the best option for non-contact high spatial
resolution thermometry in general [155] and intracellular thermometry in particular [156].
There are several types of luminescent thermometric probes according to their nature: lumi-
nescent molecules (organic molecules such as dyes, proteins like green fluorescence protein,
GFP), inorganic compounds (quantum dots, Si-dots, nanodiamond, lanthanides) or hybrid
molecular or particulate materials. Several temperatures sensing optical properties are also
used, such as the intensity of emission, lifetime or polarization anisotropy [157]. Lifetime
measurements offer high sensitivity and minimize interferences from other luminophores
present in the medium. This is especially true when using lanthanides luminescence probes
as they show long lifetimes, eliminating any interference effects from other luminophores.
However, lifetime measurements require a sophisticated detection system, and therefore
intensity measurements, which can be performed on widely available fluorescence micro-
scopes, are usually preferred. The simplest fluorescence thermometric system is based
on single emission intensity measurements, but this system does not yield absolute tem-
peratures, and it is likely to be affected by the concentration of emitters, the intensity of
excitation light source and the environment. A way to overcome these problems is to use
the ratio of two emissions as the thermometric parameter (ratiometric thermometry), which
is far more reliable, especially when the double emission comes from a single source.
There are several ways to implement luminescence nanothermometry into a magnetic
nanoheater: the dual-particle approach and the single-particle approach [157]. There are
also several kinds of temperature measuring [155–157,169]: indirect single temperature
value, direct instant, continuous measurements of temperature changes, and in situ ratio-
metric absolute temperature measurements. In the next section, we will consider the best
available options so far for magnetic hyperthermia applications.
7.3. Determination of Local Temperature in MNPs
When conveniently endorsed with targeting agents, magnetic NPs have the capacity
to selectively penetrate the membrane of cancer cells. Providing that they can be directed
to specific intracellular organelles, the heat generated by these NPs can be used to induce
local damage in these organelles originating cell apoptosis without the need of increasing
the temperature of the whole cell and thus substantially reducing the amount of MNPs
necessary to kill the cells. To verify this hypothesis, it is necessary to check whether the
heat generated by the MNPs is sufficient to maintain a temperature gradient between
the targeted organelle against the heat conduction to the cytoplasm and the extracellular
matrix. Moreover, this concept of local hyperthermia therapy with AC fields requires
the use of MNPs with a high SLP at conditions compatible with in vivo treatment. Dual
MNP-thermometer nanoparticle systems lack precision as the temperature is measured
at a distance from the heater [167]. Single-particle systems based on the detachment of
fluorophores from the MNP shell above certain temperature values have been used to
obtain temperature gradients of about 45 ◦C [166] and 8 ◦C [167] in the vicinity of MNPs
under AC magnetic field induction. However, these methods require post-analysis of the
medium and therefore cannot be used for temperature monitoring. The ideal solution
is to incorporate in a single MNP a thermometric probe that yields instant information
of the local absolute temperature of the MNP during the application of the alternating
magnetic field. There are two possible ways: decorating the MNP surface with molecular
thermometers or coating it with a solid thermometric shell. The second case would offer
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better chemical stability against the complex intracellular environment, but it is still at the
stage of finding an adequate inorganic thermometric coating for MNPs. Molecular lumi-
nescence probes may suffer from luminescence quenching and bleaching effects produced
by chemicals in the environment. Therefore, the real challenge in the design of this type
of probes is to shield them against the action of the complex biological environment to
preserve their optical thermometric properties.
As introduced in Section 7.2, several types of materials have been proposed as tem-
perature nanoprobes [156], some of them have been even used for intracellular thermom-
etry [170], i.e., ER thermo yellow [171], but only a few have been actually used in local
magnetic hyperthermia studies [170]. For instance, reports of a 15 ◦C temperature gradient
were reported on Mn-ferrite NPs attached to the membrane of HEK 293 cells 15 s after
the application of AC fields using DyLight549 as a thermometric probe [164]. Advances
in this case also include the in situ measurement of local temperature gradients using
rhodamine [172] and lanthanide luminescence complexes [169]. The emission lifetime of
GFP has also been used to report large local temperatures of 85 ◦C, although they were
estimated by extrapolation of calibration curves obtained at much lower temperatures. The
probes were not attached to the heathers, but independently spread inside the cells. Using
a double particle approach, consisting of MNPs and upconversion nanoparticles embedded
in a silica matrix, and ratiometric temperature determination, gradients of about 20 ◦C were
reported on nanoparticles suspended in a liquid after a 5 min exposure to AC fields [168].
Ongoing intracellular experiments in our lab using similar nanoprobes have yielded quite
promising results on 2D-temperature imaging of cells containing MNPs during hyperther-
mia treatment (Figure 6). Most of the thermometric probes described so far are based on
visible light, lacking the necessary tissue penetration for body temperature monitoring, and
therefore can only be useful in cell culture experiments. However, the field is also moving
towards the development of infrared deep tissue thermometry systems [173]. This option is
possible in the case of optical hyperthermia, where single nanoparticles with a heating and
temperature measurement properties are already available [174]. Infrared luminescence
temperature probes can also be possibly coupled to magnetic heating nanoparticles.
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We can reasonably expect that in a few years, we would dispose of several types
of MNPs incorporating local temperature probes, both molecular and solid nature, that
can yield reliable data on the local temperature gradient generated by MNPs exposed to
alternating magnetic fields that can be used for the development of less invasive, more
efficient and more selective advanced magnetic hyperthermia treatments.
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8. Treatment Planning and Dosimetry
Treatment planning—which reproduces the dose needed to destroy the tumors pre-
serving as much healthy tissue as possible—for many hyperthermia modalities have
benefitted from the developments made in radiotherapy [175–179]. In the particular case
of magnetic hyperthermia, so far, there is only one commercially available system for the
purpose developed by MagForce, the NanoPlan® (formerly known as HyperPlan®) [180].
The typical workflow of a hyperthermia treatment planning (HTP) tool starts with a 3D
model of the region of interest that is built from computerized tomography (CT), or MRI
scans from patients; then, electromagnetic fields, SAR and temperature distributions are
computed by solving Maxwell’s and bioheat equations, respectively, under the appropriate
boundary conditions. Regarding the virtual models used, a more or less extensive col-
lection is available throughout the literature—see, for instance, review [181]. The use of
these patient-based models—despite adding complexity to the HTP process—has been
demonstrated to improve the estimation of SAR and temperature patterns compared to
homogeneous phantom-based models [182]. Many physical models used for simulating the
interaction of the applied electromagnetic fields with tissues have been proposed [183–188],
mainly by deriving from fundamental equations, like Maxwell’s equations—for calcu-
lating electromagnetic fields and SAR—and Penne’s bioheat equation—for temperature
distributions. Unfortunately, modeling magnetic hyperthermia within the context of this
body of knowledge still proves difficult mainly due to an important challenge: to couple
the different size scales—from 3D down to 1D, where the relevant magnetic and heating
phenomena stem from—involved in the multiple physical phenomena converging in this
therapy, namely fluid dynamics, heat exchange, and electromagnetic interaction. Due
to its inherent complexity, this is a longstanding problem that needs to be addressed in
the short-term to move towards wider clinical adoption of magnetic hyperthermia. A
unified magnetic hyperthermia theory should be made possible in the near future, taking
advantage of 3D-1D coupling strategies based on topological model reduction [189].
New HTP systems based on convolutional neural networks and deep-learning tech-
niques are being tested in a new clinical trial focused on the treatment of locally advanced
pancreatic ductal adenocarcinomas [2], allowing to obtain a 3D model for each patient
instead of relying on the standard ones already available to perform the simulations. The
main benefit of the HTP is that all cases can be studied beforehand, even those that match
with any of the exclusion criteria, thus evaluating their risk and finally ruling out or not
their suitability for the treatment. One of the exclusion criteria for prospective participants
is that no implant-bearing patients are allowed, which may represent a proportion as high
as 60% of the initial cohort. The reason for this is that part or totally metallic implants may
undergo noticeable heating during the therapy upon being exposed to the magnetic field
needed to excite the MNPs (Figure 7), even inducing tissue damage if not properly con-
trolled. Very recent results show how the implant heating process takes place in different
indications, and different ways to recover a sizeable percentage of the initially excluded
patients have been proposed [190,191].
Future big improvements in treatment planning for magnetic hyperthermia are on
their way, coming from the hand of specific emerging nano-enabled diagnostic techniques,
like the case of magnetic particle imaging (MPI). The latter specifically adds what treatment
planning in magnetic hyperthermia is currently lacking, namely the precise quantification
and spatial location of the nanoparticles inside the body depending on the administration
means and the physical properties of the tissues involved [192]. This feature allows for a
preliminary quality check of nanoparticle installation inside tumors, basing the predictions
on the number of nanoparticles that have actually reached the target and not the rough
estimations made from the expected spread of the injected volume. In addition, the
possibility of a real-time follow-up of the post-injection fate of nanoparticles is crucial to
correct the initial conditions for simulating subsequent treatment sessions. Considering
that the development of MPI scanners for humans is currently moving on [193–195], the
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first results from incorporating it into the current HTP methodologies may be seen in about
two years.
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Figure 7. Calculated field and temperature patterns in and around the hip implant of a prospective patient of magnetic
hyperthermia to treat a prostate tumor.
Another significant step-up in HTP for magnetic hyperthermia could be achieved
in the near future by combining the existing technology with radiomics. The latter com-
prises computer-assisted medical image analysis with dedicated algorithms for feature
extraction—much benefitted from the boom of artificial intelligence—providing spatial
and temporal information that is not attained by data from -omics [196,197]. Radiomics
mainly nurtures from computer tomography and magnetic resonance imaging data, but
applying its principles to MPI may bring an unprecedented degree of accuracy to HTP in
magnetic hyperthermia.
9. Further Evolut on into Th ranostics: Combining Magnetic Hyperthermi and MPI
Combining therapy and diagnostic imaging, or theranostics has been an active area of
research across numerous biomedical fields over the past decade. For example, theranostics
is an established approach in nuclear medicine whereby therapy and diagnostic imaging
are performed using the same molecule or similar molecules. Theranostic agents enable
simultaneous assessment of clinical status, treatment, and confirmation of treatment dose.
In this section, we discuss a new theranostic approach that combines MPI and localized
magnetic hyperthermia. Together, these two technologies enable mapping of a MNP
distribution, prescribing a heating dose, and then carefully applying heat per the prescribed
heat dose to a local area.
MPI is an emerging imaging technology that directly quantitates MNP concentration
in tissue. MPI is tracer-based and produces positive contrast images, analogous to nuclear
medicine or optical. The signal is directly detected from the nanoparticle tracers and has
the advantage of being linearly quantitative without tissue attenuation. The physics that
underlie the signal generation and image formation can be understood using classical
physics. An MPI system produces a strong magnetic field gradient containing a field-free
region (FFR)—a region where the magnetic field is approximately zero (Figure 8a). MNPs
in the FFR are magnetically unsaturated and produce a signal in a receiver coil, while
saturated superparamagnetic iron oxide nanoparticles (SPIOs) outside the FFR produce no
signal. Images are produced by raster scanning the FFR across the subject. First published in
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2005 [198], the field has grown rapidly, and there are now commercially available preclinical
MPI systems [199,200], and clinical-scale MPI systems are under development [193,194].
To date, most MPI has been performed to non-invasively image the distribution and
quantity of MNPs in murine models. Tumors can be detected by the passive accumulation
of tracers through the enhanced permeability and retention effect [201], by the uptake
of phagocytic tumor-associated macrophages [202], or through the targeted use of func-
tionalized and targeted tracers [203,204]. Novel nanoparticles enable new capabilities for
MPI systems. Song et al. demonstrated the synthesis of multimodal FeCo nanoparticles
for imaging with near-infrared, MPI, MRI, and photoacoustic techniques and therapeutic
properties with photothermal and magnetothermal systems [205].
As previously discussed, magnetic hyperthermia for activation of MNPs offers consid-
erable potential for numerous biomedical applications, especially in the clinical treatment
of cancers. Magnetic hyperthermia relies on the delivery of MNPs to tumors followed
by the application of AC fields, causing local heating of tissue. The killing of tumor cells
occurs either directly or by enhancing the cytotoxic effects of radio, immune, or chemother-
apy [206]. Magnetic hyperthermia can be performed anywhere in the body since AC
fields penetrate tissue without attenuation. Human clinical trials have demonstrated the
benefits of magnetic hyperthermia for prostate cancer [207]; and, overall survival benefits
with radiotherapy in recurrent glioblastoma resulted in European regulatory approval in
2010 [208]. Despite its demonstrated effectiveness, current magnetic hyperthermia imple-
mentations are limited by the accumulation of MNPs away from the lesion of interest, the
inability to visualize MNP distribution during treatment, and limited ability to monitor
tissue temperature [209]. These limitations result in poor MNP heating control, reduced
therapeutic effect, and increased collateral damage.
Recent advances have demonstrated that applying the strong gradient magnetic field
used for imaging in MPI during magnetic hyperthermia enables localized magnetic hyper-
thermia, which can help overcome many of the limitations faced by traditional magnetic
hyperthermia technologies. Localized magnetic hyperthermia allows researchers to exert
spatial control over which MNPs are heated with millimeter-scale resolution [210–212]. Tay
et al. demonstrated the use of a magnetically localized magnetic hyperthermia system to
spatially localize heat deposition to a tumor while avoiding heat deposition to the healthy
liver [212]. Further, the heat dose can be optimized in real time by moving, expanding, or
contracting the size of the FFR, changing the heating region accordingly.
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Further improvements in the accuracy of treatment can be made by combining both
MPI and localized magnetic hyperthermia for a complete theranostic workflow that com-
bines imaging, treatment prescription, and application of therapy (Figure 8b). The impor-
tant linking factor across the two technologies is the availability of MNPs that are both
visible in MPI and capable of being heated via magnetic hyperthermia [209,213]. In addition
to nanoparticle biodistribution, the MPI signal contains information on the MNP’s microen-
vironment and a combined MPI, and magnetic hyperthermia can enable non-invasively
measuring temperature during heating [212,214,215]. Accurate temperature measurement
is particularly important to prevent over- and under-treatment of tumors whether the
tissue is being heated to apoptosis or as an immune-stimulating adjuvant therapy.
The combination of MPI, magnetic hyperthermia and localized magnetic hyperthermia
opens new directions for both research and clinical treatment. In research, new applications
are possible such as a novel, magnetic hyperthermia actuated nanotherapeutics capable of
the localized release of drugs or expression of heat-sensitive genetic promotors. Ultimately,
as MPI and localized magnetic hyperthermia are clinically translated, we can expect
workflow similar to X-ray/CT guided Radiation Therapy.
10. Standardization of Magnetic Colloids for Magnetic Hyperthermia
10.1. General Aspects
The need for standardization of MNPs for magnetic hyperthermia forms part of a
much broader demand for reliable, reproducible, stable and well-characterized nanostruc-
tured magnetic materials for use in emerging applications in medicine and other highly
demanding sectors. However, standardization also includes the provision of well-defined
and reproducible measurement methods for the characterization of the materials. These
methods are required to reliably determine magnetic (and structural) parameters of refer-
ence materials and of the MNPs employed in magnetic hyperthermia. This standardization
need, the related science of MNPs and their characterization have been previously explored
in some detail [216,217]. In the following subsections, the key tools available to aid in real-
izing the standardization of MNPs for hyperthermia therapy will be described. Combined,
the steps described here form a roadmap for the future realization of a measurement and
standardization infrastructure for MNPs for hyperthermia therapy.
10.2. Validating Metrological Traceability at Key Laboratories
While not a realistic goal to be achieved at every measurement laboratory in the
characterization community, it is of great importance that the metrological traceability
to SI units of at least some measurement laboratories is demonstrated for each involved
characterization technique. National metrology institutes are typical locations for this
work to be undertaken, as they combine the expertise, equipment and resources necessary
to undertake this critically important work. This is the only possible way to truly verify
that measurements are accurate, quantitative and coherent, with verified uncertainties.
European metrology institutes already have a generalized framework in place for under-
taking this kind of work, which has previously been applied to other areas of industry
with great success. Hence, far, none of the magnetic measurements for MNPs have been
metrologically validated on calibrated instruments, while some preliminary work on other
non-magnetic characterization techniques has already been undertaken [218]. Establishing
metrological traceability to SI units for key characterization techniques is necessary to
validate MNPs for hyperthermia therapy. This work is of utmost importance to achieving
standardization and deserves the highest priority. The early involvement of the relevant
end-user industry figures will ensure the long-term success of the validation work.
10.3. Interlaboratory Ring Comparisons to Harmonize Measurements
In addition to establishing metrological traceability at individual key laboratories,
developing an understanding of the overall level of measurement agreement, accuracy
and repeatability across the entire measurement community must also be achieved. Ring
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comparisons (also called interlaboratory comparisons) are the proven tool for undertaking
this type of work. By distributing identical sample sets to multiple laboratories and
monitoring the findings, a huge amount of information can be obtained. By changing
variables such as the use of in-house or centrally developed operating procedures, the
extent of uncertainties introduced by measurement apparatus, measurement procedures
and analysis methods can be isolated, understood and mitigated.
To date, ring comparisons have been performed for various nanoparticle parame-
ters relevant to hyperthermia characterization, including DLS [219], static magnetization,
SLP/ILP and AC susceptibility measurements. Alarmingly, these studies have revealed
a strong need for further harmonization to achieve interlaboratory agreement. Regular
ring comparisons are the only realistic way to monitor progress in the harmonization of
nanoparticle characterization techniques and reveal the extent of interlaboratory variations.
10.4. Development of Reference Materials
To date, no verified or accepted reference materials exist for any of the properties of
MNPs relevant for magnetic hyperthermia therapy. Reference material is characterized by
being homogeneous and stable with respect to a certain material characteristic: this can be
a physical quantity like the initial magnetic susceptibility, but it can also be a performance
characteristic like colloidal stability. For reference materials with defined physical proper-
ties, it is desirable to have a certified measurement of this property (made with calibrated
instruments in a manner that is metrologically traceable to SI units), together with an
accurately rendered uncertainty. Materials for which this type of validated measurement
has been conducted, and which are validated as being stable, are called certified reference
materials (CRM). CRMs are indispensable for verifying the accuracy and temporal stability
of individual measurement equipment, for achieving successful ring comparisons and
accurately assessing in-house quality assurance systems.
At present, large manufacturers of MNPs use their own in-house reference materials to
verify their magnetic properties measurements. Smaller companies and academic institutes
typically rely on other commercial MNP products as quasi-reference materials while lacking
detailed knowledge about the actual batch-to-batch or temporal stability of the material.
The development of validated CRMs for magnetic nanoparticle properties will benefit all
levels of industry and research and is vital to the large-scale manufacturing of medical-
grade MNP materials suitable for magnetic hyperthermia therapy. The development of
CRMs for this purpose, therefore, deserves to be the focus of significant effort in the coming
years.
10.5. Calibration and Certification of Measurement Devices and Services
Industrially accepted testing laboratories typically operate under strict systems for
quality control and management. Guidance to inform best practice in developing these
systems for biomedical products is available from ISO [220]. Laboratories that adhere to
these quality standards can gain accreditation from national bodies that operate under
mutual recognition agreements provided by the International Laboratory Accreditation
Cooperation (ILAC) to ensure that laboratories produce results that are of a known quality
that is regularly monitored. The level of standardization in the MNP manufacturing and
characterization communities is not yet sufficiently advanced for this step to be possible.
The requirements laid out in points 10.2 to 10.4 must be realized first. Given the economic
importance of MNPs and technologies which rely on them, it is in itself a striking finding
that not one laboratory in the world can currently issue accredited test certificates for the
hyperthermia performance of MNPs or related characteristics.
10.6. Development of European and International Standards Documents
Laying arguably at the pinnacle of the standardization mountain, document standards
issued by ISO, CEN (the European Committee for Standardization) or other national or
international bodies present in clear terms the agreed best practices for a diverse variety
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of industries. Until very recently, no document standards relating to the definition or
measurement of the magnetic properties of nanoparticles existed. In the last few years,
work has begun on a new series of ISO standards to address this need. The ISO 19,807
series presently consists of one published guidance document [32] detailing terminology
and appropriate measurement techniques, with a second application-specific document
specifying the needs for nanoparticles destined for nucleic acid extraction currently being
prepared [221]. In ISO 19807-1, magnetic hyperthermia is defined as the process where a
time-varying magnetic field of frequency f and amplitude H0 results in a temperature T
increase of a magnetic nanosuspension. Furthermore, the document contains a definition of
SLP as being the heating power of a magnetic nanosuspension per unit mass in response to
a time-varying magnetic field of frequency f and amplitude H0. In this definition, the unit
mass can relate to the whole nanosuspension, to the solid content or to other compartments
of the nanosuspension. It should be indicated which mass is used in reporting the result of
a specific loss power measurement. In addition to the SLP, also the ILP may be reported,
which is given by Equation (1):





When reporting the SLP or ILP parameter, also the initial temperature of the mag-
netic nanosuspension before the heating, as well as frequency f and amplitude H0 of the
excitation field, should be indicated. These are definitions of the governing hyperthermia
parameters of an MNP suspension. Hence, far, there is no specification for standardized
measurements, which remains a task of the future. In addition, issues like MNP concentra-
tion and properties of the suspending fluid are not considered in these definitions.
As future progress is made in addressing the standardization tasks detailed in point
10.2 to 10.4, opportunities to develop new document standards to detail the best practices
for reference material preparation, conducting specific characterization measurements and
other application-specific documents are expected to develop. By engaging with their
national standardization institutes, stakeholders from both industry and academia can take
part in this ongoing effort and influence the final agreements in best practice for magnetic
nanoparticle products.
For the standardization of MNPs for magnetic hyperthermia, validated metrology of
the heating properties of MNP is a necessary prerequisite. Key laboratories at National
Metrology Institutes and other expert groups should demonstrate their proficiency in SLP
measurements via interlaboratory comparisons using reference materials. Harmonized
measurement procedures for SLP measurements on calibrated devices under strict quality
assurance should be codified in international document standards. The work to implement
the elements of MNP hyperthermia metrology is only at the beginning. Since the first
clinical studies on magnetic hyperthermia-based cancer therapies are ongoing, it is of great
importance to soon achieve a reliable and reproducible quantitative assessment of the
physical properties of the involved MNPs. This will not only improve the safety of the
patients but also lead to better opportunities for MNP manufacturers and hyperthermia
equipment suppliers.
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AFM Atomic force microscopy
AGM Alternating gradient magnetometery
Cryo-TEM Cryogenic transmission electron microscopy
DCS Differential centrifugal sedimentation
DLS Dynamic light scattering
EBSD Electron backscatter diffraction
EDX Energy dispersive X-ray spectroscopy
EELS Electron energy loss spectroscopy
EXAFS Extended X-Ray absorption fine structure
EPM Electrophoretic mobility
EPLS Elliptically polarized light scattering
FMR Ferromagnetic resonance
FTIR Fourier Transform Infrared Spectroscopy
HRTEM High resolution transmission electron microscopy
ICP-OES Inductively coupled plasma optical emission spectrometry
ICP-MS Inductively coupled plasma mass spectrometry
ICP-AES Inductively coupled plasma atomic emission spectroscopy
ILP Induced loss power
IONPs Iron oxide nanoparticles
LEIS Low-energy ion scattering
MALDI Matrix-assisted laser desorption/ionisation
MH Magnetic Hyperthermia
MFM Magnetic force microscopy
MNPs Magnetic Nanoparticles
MRI Magnetic resonance imaging
NMR Nuclear magnetic resonance
NTA Nanoparticle tracking analysis
PTA Particle tracking analysis
RMM-MEMS Resonant mass measurement microelectro-mechanical system
SANS Small angle neutron scattering
SAR Specific absortion rate
SAXS Small angle X-ray scattering
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SEM Scanning electron microscopy
SEM-EDX Scanning electron microscopy - Energy dispersive X-ray spectroscopy
SIMS Secondary ion mass spectrometry
SLP Specific loss power
SOP Standard operating procedure
STEM Scanning transmission electron microscopy
SQUID Superconducting quantum interference device
TEM Transmission electron microscopy
TGA Thermogravimetric analysis
TRPS Tunable resistive pulse sensing
UV-vis Ultraviolet–visible spectroscopy
VSM Vibrating sample magnetometry
XRD X-Ray diffraction
XMCD X-Ray magnetic circular dichroism
XPS X-Ray photoemission spectroscopy
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